Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.64 |
| ▸ | HRH1 | P35367 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL613009 | 0.85 | SLC6A4 (0.58) | SLC6A4HRH1ALDH1A1HTR2ACYP1A2 | |
| SCHEMBL4612931 | 0.83 | SLC6A4 (0.50) | SLC6A4HRH1HTR2ATAAR1SLC6A2 | |
| SCHEMBL16721029 | 0.82 | SLC6A4 (0.64) | SLC6A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11081859 | 0.82 | SLC6A4 (0.69) | SLC6A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5010699 | 0.82 | SLC6A4 (0.64) | SLC6A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12506240 | 0.79 | SLC6A4 (0.65) | SLC6A4HRH1ALDH1A1HTR2ACYP1A2 | |
| SCHEMBL5010133 | 0.78 | SLC6A4 (0.58) | SLC6A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3095729 | 0.77 | HRH1 (0.52) | SLC6A4HRH1ALDH1A1HTR2ASLC6A2 | |
| SCHEMBL15171136 | 0.76 | ALDH1A1 (0.47) | SLC6A4ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5384063 | 0.76 | ALDH1A1 (0.47) | SLC6A4ALDH1A1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. | 2006-12-21 | — | — | US | disclosed |
| EP-1014966-B1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | ALLELIX NEUROSCIENCE INC (US) | 2006-08-02 | — | — | EP | disclosed |
| US-7019024-B2 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| CN-1327383-A | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALERICS NEUROSCIENCE CO (US) | 2001-12-19 | — | — | CN | disclosed |
| EP-1014966-A4 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | ALLELIX NEUROSCIENCE INC (US) | 2001-10-04 | — | — | EP | disclosed |
| US-20010012857-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | NPS PHARMACEUTICALS, INC. | 2001-08-09 | — | — | US | disclosed |
| US-6191165-B1 | ANTIDEPRESSANTS; SCHIZOPHRENIA; ALZHEIMER'S DISEASE; ANTIEPILEPTIC AGENTS | ALLELIX NEUROSCIENCE INC. | 2001-02-20 | — | — | US | disclosed |
| EP-1014966-A1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | Allelix Neuroscience Inc. (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1997045115-A1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | TROPHIX PHARMACEUTICALS, INC. (US) | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | SLC18A2, SLC6A1, SLC6A11 | SLC6A4 9/4885HRH1 884/4885ALDH1A1 806/4885 |
| US-20010012857-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | SLC6A1, SLC18A2, SLC6A11 | SLC6A4 14/4885HRH1 877/4885ALDH1A1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.